Anika Therapeutics [ANIK] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

Anika Therapeutics Inc.

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Anika Therapeutics Inc. wins in 8 metrics, Haleon Plc - ADR wins in 11 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Anika Therapeutics Inc. Haleon Plc - ADR Better
P/E Ratio (TTM) N/A 18.72 N/A
Price-to-Book Ratio 1.48 1.88 Anika Therapeutics Inc.
Debt-to-Equity Ratio 18.30 52.37 Anika Therapeutics Inc.
PEG Ratio 38.33 15.42 Haleon Plc - ADR
EV/EBITDA -32.06 33.08 Haleon Plc - ADR
Profit Margin (TTM) -9.64% 15.11% Haleon Plc - ADR
Operating Margin (TTM) 2.11% 23.17% Haleon Plc - ADR
EBITDA Margin (TTM) 2.11% 23.17% Haleon Plc - ADR
Return on Equity -6.71% 10.27% Haleon Plc - ADR
Return on Assets (TTM) -3.52% 4.67% Haleon Plc - ADR
Free Cash Flow (TTM) $4.36M $2.22B Haleon Plc - ADR
Dividend Yield N/A 1.63% N/A
1-Year Return 34.68% -16.01% Anika Therapeutics Inc.
Price-to-Sales Ratio (TTM) 1.96 3.78 Anika Therapeutics Inc.
Enterprise Value $175.41M $122.54B Haleon Plc - ADR
EV/Revenue Ratio 1.56 8.23 Anika Therapeutics Inc.
Gross Profit Margin (TTM) 62.65% 55.38% Anika Therapeutics Inc.
Revenue per Share (TTM) $8 $2 Anika Therapeutics Inc.
Earnings per Share (Diluted) $-0.70 $0.50 Haleon Plc - ADR
Beta (Stock Volatility) 0.28 0.33 Anika Therapeutics Inc.
Short % of Float 6.11% 0.43% Haleon Plc - ADR

Anika Therapeutics Inc. vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

ANIK
HLN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Anika Therapeutics Inc.-0.75%0.07%-2.01%1.74%52.66%56.26%
Haleon Plc - ADR-0.66%2.02%1.23%-13.29%-7.73%-9.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Anika Therapeutics Inc.34.68%-44.60%-63.19%-70.02%116.79%39.13%
Haleon Plc - ADR-16.01%8.43%23.21%23.21%23.21%23.21%

Performance & Financial Health Analysis: Anika Therapeutics Inc. vs Haleon Plc - ADR

MetricANIKHLN
Market Information
Market Cap i$221.65M$42.40B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i104,9656,594,249
90 Day Avg. Volume i117,5527,985,230
Last Close$14.61$9.07
52 Week Range$7.87 - $16.24$8.65 - $11.28
% from 52W High-10.04%-19.59%
All-Time High$75.72 (Oct 21, 2019)$11.42 (Jun 02, 2025)
% from All-Time High-80.71%-20.58%
Growth Metrics
Quarterly Revenue Growth0.10%0.01%
Quarterly Earnings Growth-24.73%0.86%
Financial Health
Profit Margin (TTM) i-0.10%0.15%
Operating Margin (TTM) i0.02%0.23%
Return on Equity (TTM) i-0.07%0.10%
Debt to Equity (MRQ) i18.3052.37
Cash & Liquidity
Book Value per Share (MRQ)$10.33$4.99
Cash per Share (MRQ)$4.29$0.15
Operating Cash Flow (TTM) i$11.19M$3.56B
Levered Free Cash Flow (TTM) i$13.28M$1.89B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: Anika Therapeutics Inc. vs Haleon Plc - ADR

MetricANIK (Apr 26, 2026)HLN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A18.72
Forward P/E i38.3315.42
PEG Ratio i38.3315.42
Price to Sales (TTM) i1.963.78
Price to Book (MRQ) i1.481.88
Market Capitalization
Market Capitalization i$221.65M$42.40B
Enterprise Value i$175.41M$122.54B
Enterprise Value Metrics
Enterprise to Revenue i1.568.23
Enterprise to EBITDA i-32.0633.08
Risk & Other Metrics
Beta i0.280.33
Book Value per Share (MRQ) i$10.33$4.99

Financial Statements Comparison: Anika Therapeutics Inc. vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricANIK (2025)HLN (2025)
Revenue/Sales i112.82M11.03B
Cost of Goods Sold i49.01M3.95B
COGS % of Revenue i43.4%35.8%
Gross Profit i63.81M7.08B
Gross Margin i56.6%64.2%
Research & Development i25.77M316.00M
Operating Income (EBIT) i-11.05M2.41B
Operating Margin i-9.8%21.9%
EBITDA i-5.32M2.81B
EBITDA Margin i-4.7%25.5%
Pre-Tax Income i-9.31M2.15B
Pre-Tax Income % of Revenue i-8.2%19.5%
Income Tax i672,000472.00M
Income Tax % of Revenue i0.6%4.3%
Net Income (Profit) i-10.88M1.68B
Profit Margin i-9.6%15.2%

Balance Sheet & Liquidity Metrics

MetricANIK (2025)HLN (2025)
Cash & Equivalents i57.48M1.26B
Total Current Assets i103.36M4.55B
Total Current Assets % of Revenue i91.6%41.3%
Total Current Liabilities i21.91M4.93B
Total Current Liabilities % of Revenue i19.4%44.7%
Long-Term Debt i24.20M7.75B
Long-Term Debt % of Revenue i21.4%70.2%
Total Shareholders Equity i143.47M16.48B
Retained Earnings i60.79M27.85B
Retained Earnings % of Revenue i53.9%252.5%
Property, Plant & Equipment i75.44M1.00M

Cash Flow Statement Comparison

MetricANIK (2025)HLN (2025)
Operating Cash Flow i4.44M2.19B
Operating Cash Flow % of Revenue i3.9%19.8%
Capital Expenditures i-6.83M-322.00M
Free Cash Flow i4.36M2.22B
FCF Margin i3.9%20.1%
Debt Repayment iN/A-1.35B
Common Stock Repurchase i-9.49M-654.00M

Short Interest & Institutional Ownership Analysis

MetricANIKHLN
Shares Short i688,32519.28M
Short Ratio i5.322.14
Short % of Float i6.11%0.43%
Shares Outstanding i13.89M8.91B
Float Shares i11.35M8.86B
% Held by Insiders i5.41%0.01%
% Held by Institutions i92.74%12.74%
% Held by Public i1.85%87.25%

Dividend Analysis & Yield Comparison: Anika Therapeutics Inc. vs Haleon Plc - ADR

MetricANIKHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025